Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

25 results for "Cancer" and "Eye/Orbital Cancers"

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors

This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers

A Multi-Center, Open Label Phase 1/2 Study of Cyt-0851, an Oral Rad51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Sarcoma, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers

A Phase I Study of GNX102 in Patients with Advanced Solid Tumors

This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.

The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Protocol No
GLYCONEX-GNX-001
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Gynecologic Cancers

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Lo

Evaluate the safety and tolerability of single-agent SRK-181 and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and evaluate dose-limiting toxicities (DLTs) of single-agent SRK-181.
Protocol No
SCHOLARROCK-SRK-181-001
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers, Head and Neck Cancers, Gynecologic Cancers

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

The purpose of this research study is to compare any good and bad effects of giving
ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just
ipilimumab and nivolumab together. We would also like to find out what effects, good
and bad, that this combination of drugs may have on your cancer. This study will involve
the addition of the FDA approved agent nivolumab to the standard FDA approved
ipilimumab immunotherapy in the hopes that it might further improve the good effects of
the immunotherapy component of the treatment sequence. The combination of
ipilimumab and nivolumab has been shown in recent studies to produce superior
antitumor effects but also more side effects than ipilimumab alone. This combination
has received FDA approval for patients with BRAF V600 wild-type unresectable or
metastatic melanoma. This combination is under review for FDA approval for patients
with BRAF V600 mutant melanoma and is therefore still considered to be experimental
for these patients. GM-CSF is a protein that your body normally produces to signal to
your body to make white blood cells. White blood cells are very important in the body s
defense system as they help identify and destroy foreign invaders, such as bacteria,
viruses, and cells that don t belong, such as cancer cells. Injections of GM-CSF
increase your body s production of white blood cells and also help enhance the function
of the white blood cells. This research study will allow the researchers to know whether
this different approach is better, the same, or worse than the usual approach. To be
better, the study drugs should improve how long you are able to live with your cancer
compared to the usual approach. There will be about 400 people taking part in this
research study, including approximately 15 at this site.
Protocol No
ECOG-EA6141
Sub Category
Skin Cancers